The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Increase In Market Value Is Predicted For The Small Interfering Ribonucleic Acid (RNA) Market During The 2026–2030 Period?
The small interfering ribonucleic acid (rna) market has experienced significant growth in recent years. Its size is projected to increase from $18.86 billion in 2025 to $22.69 billion in 2026, at a compound annual growth rate (CAGR) of 20.3%. This expansion during the historic period can be attributed to factors such as advancements in molecular biology research, the rising prevalence of genetic and chronic diseases, early successes in rna-based therapeutics, increased research funding in genomics, and the establishment of rna interference mechanisms.
The small interfering ribonucleic acid (rna) market is projected to experience rapid expansion in the coming years, reaching $47.07 billion in 2030 at a compound annual growth rate (CAGR) of 20.0%. This projected growth is driven by factors such as a rise in regulatory green lights for rna therapies, increasing appetite for personalized medicine, the broadening of nanoparticle delivery advancements, higher capital injections from pharmaceutical firms, and the wider use of siRNA in treating infectious and rare conditions. Key trends anticipated during this period encompass the escalating clinical uptake of rna interference therapies, an intensified focus on methods for targeted gene silencing, the spread of sophisticated siRNA delivery systems, increased funding for the development of precision therapeutics, and a stronger emphasis on scalable rna production.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30394&type=smp
Which Strategic Drivers Are Supporting The Small Interfering Ribonucleic Acid (RNA) Market Development?
The increasing need for personalized medical treatments is projected to fuel the expansion of the small interfering ribonucleic acid (RNA) market in the future. Personalized medicine represents a healthcare strategy focused on customizing therapies for individual patients, considering their genetic makeup, environmental influences, and lifestyle choices to achieve better results and enhanced patient care. The escalating demand for personalized medicine stems from progress in genomic technologies, allowing for accurate detection of genetic variations and the development of specific treatments for each person. Small interfering ribonucleic acid (siRNA) plays a crucial role in advancing personalized medicine through its ability to facilitate targeted gene silencing, making it highly suitable for addressing particular genetic conditions and illnesses. By precisely halting disease-causing mRNA, it minimizes unintended effects, thereby boosting therapeutic effectiveness and improving patient results. As an illustration, in February 2024, data from the US-based nonprofit organization, the Personalized Medicine Coalition (PMC), revealed that the U.S. Food and Drug Administration (FDA) cleared 26 new personalized medicines in 2023, marking a notable rise from the 12 approved in 2022. Consequently, the heightened demand for personalized medicine is propelling the expansion of the small interfering ribonucleic acid (RNA) market.
How Is The Small Interfering Ribonucleic Acid (RNA) Market Distributed Across Key Segments?
The small interfering ribonucleic acid (rna) market covered in this report is segmented –
1) By Type: Liposome Systemic Therapy, Nanoparticle-Based Systemic Therapy
2) By Indication: Cardiovascular Diseases, Respiratory Diseases, Oncology, Neurodegenerative Diseases, Infectious Diseases
3) By End-User: Hospital, Research Institutions, Pharmaceutical And Biotechnology Companies, Academic Institutions
Subsegments:
1) By Liposome Systemic Therapy: Cationic Liposome Delivery, Neutral Liposome Delivery, Pegylated Liposome Delivery, Targeted Liposome Delivery
2) By Nanoparticle-Based Systemic Therapy: Lipid Nanoparticle Delivery, Polymer Nanoparticle Delivery, Gold Nanoparticle Delivery, Silica Nanoparticle Delivery
Which Trends Are Expected To Shape The Small Interfering Ribonucleic Acid (RNA) Market?
Leading companies in the small interfering ribonucleic acid (siRNA) therapeutics market are concentrating on obtaining regulatory clearances for innovative approaches to treat rare genetic conditions, aiming to deliver sustained effects and reduce the frequency of dosing for patients. Regulatory approvals signify official authorizations from authorities that permit a drug or therapy to be safely tested, marketed, or administered to patients. For instance, in March 2025, Alnylam Pharmaceuticals Inc., a US-based biopharmaceutical firm, received approval from the U.S. Food and Drug Administration (FDA) for Qfitlia (fitusiran), which is the first small interfering ribonucleic acid (siRNA)-based treatment designed for adults and adolescents aged 12 years and older living with hemophilia A or B, with or without inhibitors. This therapy is engineered to lower antithrombin levels, thereby enhancing thrombin generation to facilitate clot formation and decrease bleeding episodes. Qfitlia features a subcutaneous, once-every-two-month dosing regimen, offering a new, non-factor therapeutic choice for hemophilia management.
Which Companies Are Engaged In The Small Interfering Ribonucleic Acid (RNA) Market Environment?
Major companies operating in the small interfering ribonucleic acid (rna) market are Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Sanofi S.A., Sarepta Therapeutics Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Silence Therapeutics plc, Arrowhead Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Arbutus Biopharma Corporation, Evox Therapeutics Ltd., Phio Pharmaceuticals Inc., Genecon Biotechnologies Co. Ltd., Olix Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Calando Pharmaceuticals Inc., Sirnaomics Ltd.
Access The Complete Small Interfering Ribonucleic Acid (RNA) Market Report:
Which Region Is The Primary Market For The Small Interfering Ribonucleic Acid (RNA) Market?
North America was the largest region in the small interfering ribonucleic acid (RNA) market in 2025. The regions covered in the small interfering ribonucleic acid (rna) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Small Interfering Ribonucleic Acid (RNA) Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=30394&type=smp
Browse Through More Reports Similar to the Global Small Interfering Ribonucleic Acid (RNA) Market 2026, By The Business Research Company
Ribonucleic Acid Rna Sequencing Market Report 2026
Ribose Nucleic Acid Rna Based Therapeutics Market Report 2026
Nucleic Acid Isolation And Purification Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model